Target Name: MIR4668
NCBI ID: G100616114
Review Report on MIR4668 Target / Biomarker Content of Review Report on MIR4668 Target / Biomarker
MIR4668
Other Name(s): hsa-miR-4668-5p | microRNA 4668 | mir-4668 | hsa-mir-4668 | hsa-miR-4668-3p | MicroRNA 4668

MIR4668: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Inflammatory diseases such as rheumatoid arthritis, colitis, and inflammatory bowel disease have a significant impact on the health and quality of life of individuals worldwide. These conditions cause chronic pain, damage to various body parts, and can lead to other serious complications. The immune system, which is essential for protecting the body against infection and disease, becomes imbalanced in the case of inflammatory diseases, leading to an excessive response that can cause inflammation and damage.

MIR4668, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases. In this article, we will discuss the discovery, function, and potential therapeutic applications of MIR4668, as well as its potential as a biomarker for the monitoring of disease progression.

Discovery and Function

MIR4668, also known as miRNA-4668, was first identified in the blood of individuals with rheumatoid arthritis (RA) using microarray analysis. The RNA molecule is derived from the DNA and is a small non-coding RNA molecule that plays a crucial role in gene expression. MIR4668 has been shown to regulate the immune response and has been associated with the development and progression of RA.

Functional assays have shown that MIR4668 has potent anti-inflammatory effects. MIR4668 has been shown to decrease the production of pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-6 in RA patients. It also inhibits the activity of immune cells such as T-cells, which are involved in the development of RA. MIR4668 has also been shown to increase the production of anti-inflammatory cytokines such as IL-10, which can help to reduce inflammation and promote healing in the body.

Potential Therapeutic Applications

MIR4668 has the potential to be a drug target for the treatment of inflammatory diseases. By targeting MIR4668, researchers can potentially develop new treatments for RA, colitis, and other inflammatory conditions. MIR4668 has also been shown to be a potential biomarker for monitoring disease progression in inflammatory diseases. By measuring the levels of MIR4668 in the blood, doctors can track the effectiveness of new treatments and determine if the patient is responding to treatment.

MIR4668 has also been shown to have potential applications in the treatment of other inflammatory diseases such as multiple sclerosis and Crohn's disease. MIR4668 has been shown to reduce the production of pro-inflammatory cytokines in individuals with MS and Crohn's disease, which can help to reduce inflammation and promote healing.

Conclusion

MIR4668 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases. Its anti-inflammatory properties and potential as a therapeutic target make it an attractive candidate for future research. Further studies are needed to determine the exact mechanisms of MIR4668's anti-inflammatory effects and its potential as a drug. If proven to be effective, MIR4668 has the potential to revolutionize the treatment of inflammatory diseases and improve the quality of life for individuals worldwide.

Protein Name: MicroRNA 4668

The "MIR4668 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4668 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689 | MIR4690 | MIR4691 | MIR4692 | MIR4693 | MIR4694 | MIR4695 | MIR4697 | MIR4697 host gene (non-protein coding) | MIR4698 | MIR4699 | MIR4700 | MIR4701 | MIR4703 | MIR4704 | MIR4706 | MIR4707 | MIR4708 | MIR4709 | MIR4711 | MIR4712 | MIR4713 | MIR4713HG | MIR4714 | MIR4715 | MIR4716 | MIR4717 | MIR4718 | MIR4720 | MIR4721 | MIR4722 | MIR4723 | MIR4724 | MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740 | MIR4741 | MIR4742 | MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750 | MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774